Nephrotoxicity of Immune Checkpoint Inhibitors: A Disproportionality Analysis from 2013 to 2020

Qu, Jiaming; Ding, Yanming; Jiang, Kaiwen; Hao, Junxia; Li, Yuanzhi; Zhang, Aijun; Li, Zhaohang; Qi, Guanpeng; Xu, Ze; Liu, Xin; Ma, Juman; Bi, Kaishun; Li, Zuojing

doi:10.1620/tjem.254.275

Cited by 6 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, a systematic review and meta-analysis of 27 studies and a systematic review of 127 studies both found that older age increased the risk of AKI after ICIs treatment (74,76). Alternatively, in the study by Qu et al (77), males were found to be at high risk for ICI-related nephrotoxicity. This may be due to male hormones, which increased oxidative stress, activated the renin-angiotensin system, and worsened fibrosis in damaged kidneys (78).…”

Section: Risk Factors For Development Of Ici-akimentioning

confidence: 99%

Immune checkpoint inhibitors and acute kidney injury

Zhou,

Gao,

Kong

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

As a new type of anti-tumor immunotherapy, immune checkpoint inhibitors (ICIs) have improved the prognosis of multiple malignancies. However, renal complications are becoming more frequent. Nephrotoxicity often manifests as acute kidney injury (AKI), and the most common histopathological type is acute tubulointerstitial nephritis (ATIN). Based on previous studies of the incidence and potential risk factors for nephrotoxicity, in this review, we describe the mechanism of AKI after ICIs treatment, summarize the incidence, risk factors, and outcomes of AKI, and discuss the diagnosis and management of immune checkpoint inhibitors-associated acute kidney injury (ICI-AKI). In addition, we review the current status of ICIs rechallenge and the therapeutic strategies of ICIs applied in kidney transplant recipients. Finally, we emphasize the importance of collaboration between nephrologists and oncologists to guide the treatment of ICIs and the management of renal complications.

show abstract

Section: Risk Factors For Development Of Ici-akimentioning

confidence: 99%

Immune checkpoint inhibitors and acute kidney injury

Zhou,

Gao,

Kong

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Approximately 1-4% of patients receiving atezolizumab or other PD1/PD-L1 inhibitors develop acute kidney injury. Therefore, it is important to monitor serum creatinine and GFR in these patients regularly before and after treatment with atezolizumab (72,73). Another paper reported progressive pauci-immune GN following atezolizumab.…”

Section: Pd1/pd-l1 Inhibitormentioning

confidence: 99%

Renal insufficiency in breast cancer patients; a review study

Moradi,

Izadi,

Hemmati

2024

J Nephropharmacol

View full text Add to dashboard Cite

The latest statistics and estimations indicated that breast cancer occurs in one-fourth of women worldwide and is responsible for one in six cancer deaths among women. A bilateral relationship seems to exist between breast cancer pathophysiology and kidney failure. Consideration should be given to this relationship when selecting a treatment protocol. This paper reviews the association between these two factors in breast cancer patients. There are many aspects to consider in the association between breast cancer and renal insufficiency. A breast cancer patient with normal kidney function is at risk of developing kidney failure due to paraneoplastic syndromes, hypercalcemia, and in rare cases, tumor lysis syndrome (TLS). In defining the optimal treatment protocol for each breast cancer patient, clinicians should consider the patient’s basal glomerular filtration rate (GFR). Frequent renal clearance monitoring and taking immediate action at the time GFR begins to decrease will lower the rate of kidney failure in breast cancer patients. Lastly, patients with chronic kidney disease who are recently diagnosed with breast cancer may have higher morbidity and mortality compared to breast cancer patients with normal GFR. Further investigation is needed to lower morbidity and mortality in such patients.

show abstract

“…They showed that kidney adverse events were most commonly reported for nivolumab in 46.84% of cases. In the clinical application of immune checkpoint inhibitors, attention should be directed towards male patients with acute renal failure, nephritis, and other nephrotoxic adverse events since the administration of immune checkpoint inhibitors is likely to worsen their condition (27). In a recent meta-analysis, Tan et al studied the renal toxicity of combination therapy by immune checkpoint inhibitor in advanced kidney cell carcinoma cases.…”

Section: Literature Review On Kidney Adverse Events Of Immune Checkpo...mentioning

confidence: 99%

Nephrotoxicity of checkpoint inhibitors; a current challenge

Zandifar,

Imankhan,

Daneii

et al. 2023

J Nephropharmacol

View full text Add to dashboard Cite

Immune checkpoint inhibitors work by blocking the "checkpoint" mechanism that tumors use to hide from the immune system, therefore also weakening the immune system. Consequently, checkpoint inhibitors can cause autoimmune reactions, resulting in adverse effects. Prompt identification and management of adverse effects are critical for patients under checkpoint inhibitor therapy due to the potential severity and unpredictability of these immune-related adverse events.

show abstract

Nephrotoxicity of Immune Checkpoint Inhibitors: A Disproportionality Analysis from 2013 to 2020

Cited by 6 publications

References 29 publications

Immune checkpoint inhibitors and acute kidney injury

Immune checkpoint inhibitors and acute kidney injury

Renal insufficiency in breast cancer patients; a review study

Nephrotoxicity of checkpoint inhibitors; a current challenge

Contact Info

Product

Resources

About